Highlights and Quick Summary
- EPS (Diluted, from Cont. Ops) for the quarter ending June 30, 2023 was $-0.356 (a 3.25% increase compared to previous quarter)
- Year-over-year quarterly EPS (Diluted, from Cont. Ops) increased by 12.26%
- Annual EPS (Diluted, from Cont. Ops) for 2022 was $-1.14 (a 46.92% increase from previous year)
- Annual EPS (Diluted, from Cont. Ops) for 2021 was $-0.774 (a 47.56% increase from previous year)
- Twelve month EPS (Diluted, from Cont. Ops) ending June 30, 2023 was $-1.33 (a 6.99% increase compared to previous quarter)
- Twelve month trailing EPS (Diluted, from Cont. Ops) increased by 41.02% year-over-year
Trailing EPS (Diluted, from Cont. Ops) for the last four month:
| 30 Jun '23 | 31 Mar '23 | 31 Dec '22 | 30 Sep '22 |
|---|---|---|---|
| $-1.33 | $-1.24 | $-1.14 | $-0.943 |
Visit stockrow.com/DSGN
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical EPS (Diluted, from Cont. Ops) of Design Therapeutics, Inc.
Most recent EPS (Diluted, from Cont. Ops)of DSGN including historical data for past 10 years.Interactive Chart of EPS (Diluted, from Cont. Ops) of Design Therapeutics, Inc.
Design Therapeutics, Inc. EPS (Diluted, from Cont. Ops) for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2023 | $0.0 | $0.0 | – | – | – |
| 2022 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 |
| 2021 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 |
| 2020 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 |
Business Profile of Design Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology